Skip to content

Released May 14, 2026, after the close

10-Q filed May 14, 2026, 44 days after period end · 0001193125-26-224170

Q1 2026 · 10-Q
Revenue$14.52M−16.5% vs Q1 2025+24.7% vs Q4 2025
Net Income-$38.48MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$2.94N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$29,656,000N/M
Operating Cash Flow-$42,259,000N/M
Margins · derived
Operating margin-204.2%+189.6 pt vs Q1 2025
Net margin-265.0%+171.6 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$14.52M$17.40M$13.01M$12.67M
Net Income-$38.48M-$75.97M-$58.21M-$50.05M
EPS Diluted-$2.94-$9.08-$0.59-$0.85

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR